Immix Biopharma, Inc. / Fundamentals
Income statement
- Net revenue
€82.62K - Cost of goods sold
€141.50K - Gross profit
-€100.19K - SG&A expenses
€10.31M - R&D expenses
€10.10M - EBITDA
-€20.35M - D&A
€108.47K - EBIT
-€20.41M - Interest expenses
€0.00 - EBT
-€19.81M - Tax expenses
€34.89K - Net income
-€19.84M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€0.00 - Changes in working capital
€6.50M - Operating cash flow
-€10.73M - Capex
€835.72K - Other investing cash flow
€0.00 - Net investing cash flow
-€835.72K - Total cash dividends paid
€0.00 - Issuance of common stock
€952.48K - Debt repayment
€0.00 - Other financing cash flow
€13.68M - Net financing cash flow
€952.48K - Foreign exchange effects
€29.15K - Net change in cash
-€10.59M - Cash at end of period
€9.99M - Free cash flow
-€9.90M
Balance sheet
- Cash and cash equivalents
€9.99M - Cash and short-term investments
€9.99M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€589.89K - Total current assets
€10.58M - Property, plant & equipment
€2.73M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€112.42K - Total non-current assets
€2.84M - Total assets
€13.41M - Accounts payable
€5.68M - Short-term debt
€60.46K - Other current liabilities
€2.85M - Total current liabilities
€8.59M - Long-term debt
€834.26K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€834.26K - Total liabilities
€9.42M - Common stock
€2.44K - Retained earnings
-€73.95M - Other equity
€55.80K - Total equity
€3.99M - Total liabilities and shareholders' equity
€13.41M
Company information
- Market capitalization
€51.60M - Employees
18 - Enterprise Value
€52.88M
Company ratios
- Gross margin
-
-121.3% Much worse than peer group: 26,507,040,249,897,392,000.0% - EBITDA margin
-
-24,629.2% Much worse than peer group: 11,666,131,808,988,928,000.0% - EBIT margin
-
-24,699.0% Much worse than peer group: 9,950,452,121,880,664,000.0% - EBT margin
-
-23,975.4% Much worse than peer group: 2,463,829,783,772,641,000,000.0% - Net margin
-
-24,017.6% Much worse than peer group: 464,911,664,911,575,900.0% - ROE
-
-497.0% Much better than peer group: -10,492.1% - ROA
-
-147.9% Much better than peer group: -699.1% - Asset turnover
-
0.6% Much worse than peer group: 28.6% - FCF margin
-
-14,000.7% Much worse than peer group: 7,478,767,821,624,856,000.0% - FCF yield
-22.4% - Efficiency ratio
24,729.2% - Net sales per employee
-
€4.59K - Net income per employee
-
-€1.10M